新辅助化疗对乳腺癌p53、bcl-2表达的影响及其意义

The adjustment to p53/bcl-2 and its implication of neoadjuvant chemotherapy in breast cancer

目的 探讨新辅助化疗对乳腺癌p5 3、bcl 2蛋白表达的影响及其意义。方法 用免疫组织化学ABC法检测 97例术前化疗 (研究组 )和同期 76例未行术前化疗 (对照组 )的乳腺癌组织p5 3、bcl 2蛋白的表达 ,并结合 5年无病生存率 (DFS)进行分析。结果 研究组p5 3阳性率为 2 8.9% (2 8 97) ,对照组为 38.2 % (2 9 76 ) ;研究组bcl 2阳性率为4 0 .2 % (39 97) ,对照组为 5 6 .7% (43 76 ) ;研究组 5年DFS为 74 .2 % (72 97) ,对照组为 6 0 .5 % (46 76 ) ,两者比较均有显著差异。结论 新辅助化疗可能通过调节p5 3、bcl

Objective To explore the influence of neoadjuvant chemotherapy on the expression of p53/bcl-2 protein and its implication. Methods The study group which was treated with neoadjuvant chemotherapy (n=97) and the control group (n=76) were analyzed for p53, bcl-2 expression by immunohistochemistry using specific monoclonal antibodies. The 5-year disease-free survival (DFS) was also analyzed. Results P53 protein was expressed in 28 (28.9%) of 97 cases in the study group, while in the control group, p53 protein was expressed in 29 (38.2%) of 76 cases. Bcl-2 protein was expressed in 39 (40.2%) of 97 cases in the study group, while in the control group, bcl-2 protein was expressed in 43(56.7%) of 76 cases. The 5- year DFS of the study group was 74.2% (72/97), and that of the control group was 60.5% (46/76). The above all were statistically significant(P<0.05). Conclusion It is possible that p53/bcl-2 is one of the most important mediators of the neoadjuvant chemotherapy anticancer pathway.